Moyamoya Disease and von Willebrand Disease: A Groundbreaking Surgical Approach
"Discover how surgeons successfully performed a revascularization operation on a patient with both Moyamoya and von Willebrand diseases, paving the way for safer treatments."
Moyamoya disease, characterized by progressive narrowing of the arteries at the base of the brain, often requires revascularization surgery to improve blood flow and prevent strokes. However, when this condition occurs alongside von Willebrand disease (vWD), a genetic bleeding disorder, the risk of hemorrhagic complications skyrockets, presenting a significant challenge for surgeons.
Von Willebrand disease (vWD) is a genetic condition that impairs blood clotting due to a deficiency or defect in the von Willebrand factor (vWF). While surgical interventions can be risky for vWD patients, managing vWF levels during the perioperative period has shown promise in mitigating bleeding risks.
Now, a team of surgeons has successfully navigated this complex scenario, performing a revascularization operation on a patient with both Moyamoya and vWD. This article delves into their groundbreaking approach, offering insights into how they managed the increased risk and achieved a positive outcome.
Current Standards and Their Limits
The 2023 American Heart Association/American Stroke Association scientific statement describes adult moyamoya disease and syndrome as rare disorders associated with significant morbidity and mortality. It updates definitions, diagnostic methods, and the evidence base while identifying priorities for future investigation. The European Stroke Organisation guidelines, developed using the ESO standard operating procedure and GRADE methodology, are intended to support clinical decision-making in moyamoya angiopathy; von Willebrand disease management is addressed separately through ASH, ISTH, NHF, and WFH clinical practice guidelines.
Overcoming the Odds: A Surgical Success Story
In a notable case, surgeons performed a left superficial temporal artery to middle cerebral artery (STA-MCA) bypass, combined with encephalo-myo-synangiosis (EMS), on a 35-year-old woman with both Moyamoya disease and type 1 vWD. The key to their success was meticulous management of the patient's vWF levels.
- Careful vWF Management: Maintaining adequate vWF levels is crucial in preventing hemorrhagic complications in vWD patients undergoing surgery.
- Desmopressin Alternative: The European Haemophilia Therapy Strategy Board suggests using a vWF/FVIII compound over desmopressin for patients with ischemic heart disease, stroke, or related conditions.
- Individualized Approach: Monitoring vWF and FVIII levels is essential to prevent both bleeding and thrombotic events.
Evolving Research Directions
A 2026 Frontiers research topic identifies emerging work in moyamoya disease diagnosis, mechanistic understanding, and treatment innovation. It describes the field as moving beyond traditional angiographic descriptions and established surgical paradigms. A 2026 review characterizes moyamoya disease as a usually bilateral, chronic, progressive stenosis at the terminal internal carotid artery with collateralization at the skull base, while distinguishing moyamoya syndrome as the same angiographic pattern occurring with another anomaly or condition.
Rarity and Clinical Risk
The PubMed search record states that the association between moyamoya disease and von Willebrand disease is extremely rare, limiting the strength of broad conclusions from individual cases. The National Institute of Neurological Disorders and Stroke describes moyamoya disease as a rare, progressive disorder involving blocked arteries at the brain’s base and a compensatory network of tiny vessels known as “puff of smoke.” The Mayo Clinic similarly reports carotid narrowing or blockage, reduced blood flow to the brain, and development of tiny vessels at the brain’s base, with symptoms most common in children ages 5 to 10 and adults ages 30 to 50.
Diagnostic and Surgical Comparisons
The 2020 European Clinical, Laboratory and Molecular diagnostic work-up recommends a complete set of von Willebrand factor parameters to distinguish type 1, type 2, and type 3 von Willebrand disease. Listed assessments include VWF activity, factor VIII, collagen binding, ristocetin-induced platelet aggregation, multimeric analysis, and responses to DDAVP. Separate research compares VWF function in type 2A von Willebrand disease with left ventricular assist device-induced acquired von Willebrand syndrome and reports analysis of 80 moyamoya patients who underwent 134 surgical interventions to examine factors associated with effective neovascularization.
Paving the Way for Safer Neurosurgery
This case marks a significant step forward in the treatment of Moyamoya disease in patients with concurrent vWD. By demonstrating the feasibility and success of carefully managed revascularization surgery, it offers hope for improved outcomes and reduced risks for this complex patient population.
Future Diagnostic and Therapeutic Frontiers
The Frontiers research topic presents moyamoya disease as a progressive disorder involving narrowing and eventual occlusion of the terminal internal carotid arteries, followed by formation of abnormal tiny vessels at the skull base. It emphasizes the need to improve diagnostic methods and treatments. The book Moyamoya Disease: Current Knowledge and Future Perspectives covers diagnostic criteria, genetic aspects, pathophysiology, novel neuroradiological findings, surgical therapy, and recent basic and clinical research aimed at identifying future directions.
Lessons from Rare Cases
A 2019 case report describes moyamoya disease as typically involving progressive stenosis or occlusion of the terminal internal carotid artery, with patients commonly presenting with cerebral ischemia or hemorrhage. The report identifies revascularization surgery as one therapeutic option for reducing the risk of these cerebrovascular events and notes that von Willebrand disease is also a rare hemorrhagic disorder. Another 2019 report describes a 27-year-old woman with moyamoya disease concurrent with type 1 von Willebrand disease, underscoring the rarity of this combined clinical situation.
The findings underscore the importance of a comprehensive perioperative strategy that includes close monitoring and replacement of vWF, tailored to the individual patient's needs and circumstances. This approach can minimize the risk of bleeding complications and enable successful surgical interventions.
While further research is needed to refine and optimize these strategies, this pioneering case provides a valuable framework for future neurosurgical interventions in patients with both Moyamoya and von Willebrand diseases, paving the way for safer and more effective treatments.